These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 33422890)

  • 1. The value of multimodal imaging with
    Miyagawa T; Przybelski SA; Maltais D; Min HK; Jordan L; Lesnick TG; Chen Q; Graff-Radford J; Jones D; Savica R; Knopman D; Petersen R; Kremers WK; Forsberg LK; Fields JA; Ferman TJ; Allen L; Parisi J; Reichard RR; Murray M; Dickson D; Boeve BF; Kantarci K; Lowe VJ
    Neurobiol Aging; 2021 Mar; 99():11-18. PubMed ID: 33422890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Confirmation of
    Maltais DD; Jordan LG; Min HK; Miyagawa T; Przybelski SA; Lesnick TG; Reichard RR; Dickson DW; Murray ME; Kantarci K; Boeve BF; Lowe VJ
    J Nucl Med; 2020 Nov; 61(11):1628-1635. PubMed ID: 32198310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.
    O'Brien JT; Colloby S; Fenwick J; Williams ED; Firbank M; Burn D; Aarsland D; McKeith IG
    Arch Neurol; 2004 Jun; 61(6):919-25. PubMed ID: 15210531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography and (123) I-metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias: A comparative study.
    Tiraboschi P; Corso A; Guerra UP; Nobili F; Piccardo A; Calcagni ML; Volterrani D; Cecchin D; Tettamanti M; Antelmi L; Vidale S; Sacco L; Merello M; Stefanini S; Micheli A; Vai P; Capitanio S; Gabanelli SV; Riva R; Pinto P; Biffi AM; Muscio C;
    Ann Neurol; 2016 Sep; 80(3):368-78. PubMed ID: 27398636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of 99mTc-exametazime and 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies.
    Colloby SJ; Firbank MJ; Pakrasi S; Lloyd JJ; Driver I; McKeith IG; Williams ED; O'Brien JT
    Int Psychogeriatr; 2008 Dec; 20(6):1124-40. PubMed ID: 18752700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy.
    Walker Z; Jaros E; Walker RW; Lee L; Costa DC; Livingston G; Ince PG; Perry R; McKeith I; Katona CL
    J Neurol Neurosurg Psychiatry; 2007 Nov; 78(11):1176-81. PubMed ID: 17353255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study.
    McKeith I; O'Brien J; Walker Z; Tatsch K; Booij J; Darcourt J; Padovani A; Giubbini R; Bonuccelli U; Volterrani D; Holmes C; Kemp P; Tabet N; Meyer I; Reininger C;
    Lancet Neurol; 2007 Apr; 6(4):305-13. PubMed ID: 17362834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies.
    McCleery J; Morgan S; Bradley KM; Noel-Storr AH; Ansorge O; Hyde C
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010633. PubMed ID: 25632881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholinesterase inhibitor use does not significantly influence the ability of 123I-FP-CIT imaging to distinguish Alzheimer's disease from dementia with Lewy bodies.
    Taylor JP; Colloby SJ; McKeith IG; Burn DJ; Williams D; Patterson J; O'Brien JT
    J Neurol Neurosurg Psychiatry; 2007 Oct; 78(10):1069-71. PubMed ID: 17299017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.
    Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J
    J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's disease.
    Shimizu S; Hirao K; Kanetaka H; Namioka N; Hatanaka H; Hirose D; Fukasawa R; Umahara T; Sakurai H; Hanyu H
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):184-192. PubMed ID: 26233438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT.
    Morgan S; Kemp P; Booij J; Costa DC; Padayachee S; Lee L; Barber C; Carter J; Walker Z
    J Neurol Neurosurg Psychiatry; 2012 Nov; 83(11):1063-70. PubMed ID: 22869921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of semiquantitative assessment of regional binding potential in 123I-FP-CIT SPECT for the differentiation of frontotemporal dementia, dementia with Lewy bodies, and Alzheimer's dementia.
    Spehl TS; Frings L; Hellwig S; Weiller C; Hüll M; Meyer PT; Amtage F
    Clin Nucl Med; 2015 Jan; 40(1):e27-33. PubMed ID: 25140560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies.
    Lim SM; Katsifis A; Villemagne VL; Best R; Jones G; Saling M; Bradshaw J; Merory J; Woodward M; Hopwood M; Rowe CC
    J Nucl Med; 2009 Oct; 50(10):1638-45. PubMed ID: 19759102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroimaging for diagnosing dementia with Lewy bodies: What is the best neuroimaging technique in discriminating dementia with Lewy bodies from Alzheimer's disease?
    Shimizu S; Kanetaka H; Hirao K; Fukasawa R; Namioka N; Hatanaka H; Hirose D; Umahara T; Sakurai H; Hanyu H
    Geriatr Gerontol Int; 2017 May; 17(5):819-824. PubMed ID: 27138074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer's disease pathology: An
    van der Zande JJ; Joling M; Happach IG; Vriend C; Scheltens P; Booij J; Lemstra AW
    Neuroimage Clin; 2020; 25():102062. PubMed ID: 31790878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An
    Joling M; Vriend C; Raijmakers PGHM; van der Zande JJ; Lemstra AW; Berendse HW; Booij J; van den Heuvel OA
    Neuroimage Clin; 2019; 22():101755. PubMed ID: 30884365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diagnostic performance of functional dopaminergic scintigraphic imaging in the diagnosis of dementia with Lewy bodies: an updated systematic review.
    Jreige M; Kurian GK; Perriraz J; Potheegadoo J; Bernasconi F; Stampacchia S; Blanke O; Alessandra G; Lejay N; Chiabotti PS; Rouaud O; Nicod Lalonde M; Schaefer N; Treglia G; Allali G; Prior JO
    Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):1988-2035. PubMed ID: 36920494
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Pardini M; Nobili F; Arnaldi D; Morbelli S; Bauckneht M; Rissotto R; Serrati C; Serafini G; Lapucci C; Ghio L; Amore M; Massucco D; Sassos D; Bonzano L; Mancardi GL; Roccatagliata L;
    Eur Radiol Exp; 2020 May; 4(1):27. PubMed ID: 32363488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single-photon emission computed tomography brain imaging in the diagnosis of dementia with Lewy bodies.
    Walker Z; Cummings JL
    Alzheimers Dement; 2012 Jan; 8(1):74-83. PubMed ID: 22024052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.